CryoEM Confirms a First-in-Class Allosteric Binding Mode, Validating MolecuLernTM ... its first-in-class oral small-molecule GLP-1 receptor agonist. This breakthrough confirms a completely novel ...

This breakthrough confirms a completely novel allosteric activation mechanism for the GLP-1 receptor ... new chemotype with an entirely unique binding mode. Biolexis is actively completing ...

A mutagenesis study to systematically analyse residues spanning the first extracellular loop of the GLP-1 receptor identified a double mutant ... the locus is important for the formation of the ...

CryoEM Confirms a First-in-Class Allosteric Binding Mode, Validating MolecuLern™ AI-Driven Discovery LEHI, Utah , March 14, 2025 /PRNewswire/ -- Biolexis Therapeutics has achieved a transformative ...

Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved 24% weight reduction at 48 weeks in a ...

The popular anti-obesity drug Mounjaro has finally been launched in India. The development comes after Eli Lilly received ...

The farnesoid X receptor ... binding site of FXR, thereby blocking co-activator recruitment, reducing intestinal ceramide production, and promoting glucagon-like peptide-1 (GLP-1) release.

MIAMI, FLORIDA / ACCESS Newswire / April 1, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company developing ...

US pharma giant Eli Lilly's Mounjaro can prove crucial in treatment of obesity & type 2 diabetes. Launched in the US in 2022, ...

BRP emerges as a promising peptide for weight loss, activating appetite control pathways without triggering nausea, paving the way for safer obesity therapies.

Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn’s and Colitis Organization in Inflammatory Bowel ...